ProShare Advisors’s Sionna Therapeutics SION Stock Holding History

ProShare Advisors’s Portfolio SION Stock Details SION Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4,903	Closed	-$202K	–	2059
2025 Q4	$202K	Buy	+4,903	New	+$186K	﹤0.01%	1716

Other funds holding SION

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

ProShare Advisors's SION Position: Q1 2026 in Review

ProShare Advisors sold out of Sionna Therapeutics (SION) in Q1 2026, closing a stake of 4,903 shares — an estimated $202K sold.

ProShare Advisors first reported a position in SION in Q4 2025 and held it in 1 quarter. The position peaked at $202K in Q4 2025. 122 funds tracked by Wall St. Rank hold SION as of Q1 2026.

ProShare Advisors reported no remaining Sionna Therapeutics position as of Q1 2026 after selling out during the quarter.
ProShare Advisors sold 4,903 Sionna Therapeutics shares in Q1 2026, an estimated $202K.
ProShare Advisors first reported a position in Sionna Therapeutics in Q4 2025 and held it in 1 quarter.
ProShare Advisors's Sionna Therapeutics position peaked at $202K in Q4 2025.
122 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q1 2026.

Based on ProShare Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.